A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

NCT04073615 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
29
Enrollment
INDUSTRY
Sponsor class

Stopped Phase 2 portion of the study was not performed due to redirection of the rivoceranib development plan by the Sponsor.

Conditions

Interventions

Sponsor

Elevar Therapeutics